NCIt definition : A humanized monoclonal antibody (MoAb) against human epidermal growth factor receptor
(EGFR) with antineoplastic activity. Depatuxizumab targets the EGFR deletion variant,
de2-7 EGFR as well as wild-type EGFR expressed in cells overexpressing the receptor,
thereby preventing the activation and subsequent dimerization of the receptor; the
decrease in receptor activation and dimerization result in an inhibition in signal
transduction and anti-proliferative effects. This MoAb targets cells expressing aberrant
EGFR, hence making it an ideal candidate for generation of radioisotope or toxin conjugates.;